Posterior Versus Transmuscular Quadratus Lumborum Block in Children Undergoing Lower Abdominal Surgery
Analgesic Efficacy of Posterior Versus Transmuscular Quadratus Lumborum Block in Children Undergoing Unilateral Lower Abdominal Surgery: A Randomized Controlled Trial
The quadratus lumborum block (QLB) is an established regional anesthesia technique that provides somatic and visceral analgesia for abdominal wall procedures in both adult and pediatric populations. Among its standardized approaches, the posterior QLB (QL2-injectate deposited in the lumbar interfascial triangle at the posterior surface of the quadratus lumborum muscle) and the transmuscular QLB (QL3-injectate deposited in the fascial plane between the anterior surface of the quadratus lumborum and psoas major muscles) are widely utilized.
Although cadaveric and radiological studies suggest that transmuscular QLB yields greater anterior and thoracic paravertebral spread compared to the posterior approach, comparative clinical evidence in pediatric populations remains limited.
The objective of this randomized, prospective, double-blind controlled trial is to compare the analgesic efficacy of ultrasound-guided posterior QLB (QL2) versus transmuscular QLB (QL3) using an identical weight-based dose and concentration of local anesthetic (0.4 mL/kg of bupivacaine 0.25%) in children aged 1 to 7 years undergoing elective unilateral lower abdominal surgery (e.g., inguinal herniotomy, orchiopexy, hydrocelectomy). The primary hypothesis is that one approach will provide superior 24-hour cumulative opioid-sparing analgesia compared to the other.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Background and Anatomical Rationale:
Truncal fascial plane blocks like the quadratus lumborum block (QLB) play a key role in pediatric multimodal analgesia. While posterior QLB (QL2) targets the lumbar interfascial triangle (LIFT) with minimal anatomical risk to deep structures, transmuscular QLB (QL3) penetrates the QL muscle to deposit local anesthetic in the anterior fascial plane adjacent to the psoas major muscle. This study evaluates whether these anatomical differences translate into distinct clinical analgesic outcomes in pediatric patients.
Anesthetic Protocol and Block Execution:
Following standardized general anesthesia induction and airway securing, children assigned to either group receive an ultrasound-guided unilateral block in the lateral decubitus position using the classic "Shamrock" sonographic landmark view (L3 transverse process level).
Posterior QLB Group (QL2): A short-bevel echogenic needle is advanced in-plane to the posterior aspect of the quadratus lumborum muscle (QLM) within the lumbar interfascial triangle.
Transmuscular QLB Group (QL3): An identical needle is advanced transmuscularly through the QLM into the fascial plane between the anterior surface of the QL and psoas major muscle.
In both groups, plane identification is confirmed by hydrodissection (1-2 mL saline/D5W), followed by slow injection of 0.4 mL/kg bupivacaine 0.25% (1 mg/kg; maximum 20 mL) with intermittent aspiration every 3-5 mL.
Postoperative Analgesic Management and Assessment:
Postoperative behavioral pain intensity is monitored by a blinded observer using the Face, Legs, Activity, Cry, Consolability (FLACC) score at 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively. Stepwise rescue analgesia is initiated for FLACC scores ≥4: intravenous paracetamol 15 mg/kg (if >6 hours from prior dose), followed by rescue intravenous fentanyl 0.5 µg/kg or morphine 0.05 mg/kg if pain persists.
Sedation (University of Michigan Sedation Scale), motor block (modified Bromage scale), time to first rescue request, incidence of postoperative nausea and vomiting (PONV), parental satisfaction (5-point Likert scale), and time to post-anesthesia discharge readiness are systematically evaluated.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Kerollos Moneer Neseem Mikhael, MD
- Número de telefone: 00201288549959
- E-mail: Kmnmk87@med.bsu.edu.eg
Locais de estudo
-
-
-
Banī Suwayf, Egito
- Beni-Suef University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Children aged 1 to 7 years. American Society of Anesthesiologists (ASA) physical status I or II. Scheduled for elective unilateral lower abdominal surgery under general anesthesia with a planned quadratus lumborum block for postoperative analgesia (e.g., inguinal herniotomy, orchiopexy, hydrocelectomy).
Written informed consent obtained from a parent or legal guardian.
Exclusion Criteria:
Parental or guardian refusal to participate. Known allergy or hypersensitivity to amide local anesthetics. Coagulopathy or active use of anticoagulant or antiplatelet medication. Local skin infection at the intended regional block injection site. Planned bilateral surgical procedure. Significant hepatic, renal, cardiac, or neuromuscular disease. Developmental delay or medical condition precluding reliable pain-scale assessment.
Preoperative chronic opioid or regular analgesic use. Body weight below the 3rd percentile for age, or known spinal/vertebral column anomaly precluding safe block performance.
Emergency surgery.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Posterior QLB (QL2)
Children assigned to this arm receive a single-dose, ultrasound-guided posterior quadratus lumborum block (QL2) performed after induction of general anesthesia and prior to surgical incision. Under ultrasound guidance, a short-bevel echogenic needle is advanced to the posterior surface of the quadratus lumborum muscle within the lumbar interfascial triangle (LIFT). Local anesthetic is deposited following hydrodissection confirmation and negative aspiration. |
Ultrasound-guided single-injection posterior quadratus lumborum block performed pre-incisions under general anesthesia. Local anesthetic: 0.4 mL/kg of bupivacaine 0.25% (1 mg/kg; maximum single-side volume 20 mL) deposited at the posterior border of the QL muscle within the lumbar interfascial triangle.
Outros nomes:
|
|
Comparador Ativo: Transmuscular QLB (QL3)
Children assigned to this arm receive a single-dose, ultrasound-guided transmuscular quadratus lumborum block (QL3) performed after induction of general anesthesia and prior to surgical incision. Under ultrasound guidance using the "Shamrock" view, a short-bevel needle is advanced transmuscularly through the quadratus lumborum muscle to deposit local anesthetic in the fascial plane between its anterior surface and the psoas major muscle following hydrodissection confirmation and negative aspiration. |
Ultrasound-guided single-injection transmuscular quadratus lumborum block performed pre-incisions under general anesthesia. Local anesthetic: 0.4 mL/kg of bupivacaine 0.25% (1 mg/kg; maximum single-side volume 20 mL) deposited in the plane between the anterior surface of the QL muscle and psoas major muscle.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Cumulative Opioid Consumption in the First 24 Hours
Prazo: First 24 hours postoperatively
|
Total cumulative dose of intraoperative and postoperative rescue opioids administered during the first 24 hours postoperatively, converted to intravenous morphine-equivalent doses (mg/kg) using standard conversion ratios and normalized to body weight. A lower numerical value indicates a superior clinical outcome (greater opioid-sparing effect and reduced opioid requirement). |
First 24 hours postoperatively
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative Pain Intensity Scores
Prazo: At 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
Postoperative pain intensity measured using the Face, Legs, Activity, Cry, Consolability (FLACC) behavioral pain scale. Scores range from 0 to 10, where 0 represents no pain (relaxed and comfortable; best outcome) and 10 represents severe pain/discomfort (worst outcome). Lower numerical scores represent better pain control. |
At 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
|
Time to First Rescue Analgesia Request
Prazo: Up to 24 hours postoperatively
|
Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU) until the first administration of rescue analgesic (triggered by a FLACC score ≥4). A higher numerical value (longer duration of time) indicates a superior clinical outcome (prolonged block duration and delayed pain onset). |
Up to 24 hours postoperatively
|
|
Block Execution Time
Prazo: Intraoperatively (during block performance)
|
Total time required to perform the ultrasound-guided regional block, measured in seconds from initial placement of the ultrasound transducer on the skin to needle withdrawal. Lower execution times represent greater technical ease and efficiency (better procedural performance). |
Intraoperatively (during block performance)
|
|
Number of Needle Passes and Redirections
Prazo: Intraoperatively (during block performance)
|
Number of discrete needle skin punctures and forward redirections required to achieve correct needle tip positioning within the intended target fascial plane. A lower count indicates easier needle placement and less tissue trauma (better procedural outcome). |
Intraoperatively (during block performance)
|
|
Incidence and Severity of Postoperative Nausea and Vomiting
Prazo: At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
Presence and severity of postoperative nausea and vomiting assessed using a 4-point scale (0 = no nausea or vomiting [best outcome], 1 = mild nausea, 2 = moderate nausea or single emetic episode, 3 = severe nausea or multiple emetic episodes requiring antiemetic rescue [worst outcome]). Lower scores represent a better clinical outcome. |
At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
|
Postoperative Sedation Score
Prazo: At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
Sedation level evaluated using the University of Michigan Sedation Scale (UMSS), ranging from 0 (awake and alert; normal state) to 4 (unarousable to noxious stimuli; severe sedation/respiratory risk). Lower scores (specifically 0 to 1) represent desirable postoperative alertness and faster recovery. |
At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
|
Incidence and Degree of Lower Limb Motor Blockade
Prazo: At 1, 4, and 8 hours postoperatively
|
Motor weakness evaluated using a modified Bromage scale (0 = full flexion of knees and feet / no motor block [best safety outcome], 1 = partial flexion, 2 = movement of feet only, 3 = complete paralysis of lower limb [worst outcome]). A score of 0 indicates an optimal motor-sparing sensory block without unwanted lumbar plexus involvement. |
At 1, 4, and 8 hours postoperatively
|
|
Parental Satisfaction Score
Prazo: 24 hours postoperatively
|
Parental or legal guardian overall satisfaction with post-surgical pain management evaluated on a 5-point Likert scale (1 = very dissatisfied [worst outcome], 2 = dissatisfied, 3 = neutral, 4 = satisfied, 5 = very satisfied [best outcome]). Higher numerical scores represent a superior clinical outcome. |
24 hours postoperatively
|
|
Time to Post-Anesthesia Discharge Readiness
Prazo: Up to 24 hours postoperatively
|
Time elapsed (in minutes) from PACU arrival until the child satisfies all criteria of the modified pediatric Post-Anesthesia Discharge Scoring System (PADSS). A lower numerical value (shorter duration of time in minutes) indicates a better outcome (faster recovery and earlier discharge readiness). |
Up to 24 hours postoperatively
|
|
Incidence of Block-Related Adverse Events and Complications
Prazo: Through 24 hours postoperatively
|
Total count and percentage of procedural complications (including vascular puncture, LAST, peritoneal injury, localized hematoma, or infection). A lower number (ideally 0) indicates a superior safety profile. |
Through 24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Dor
- Manifestações Neurológicas
- Doenças do Sistema Endócrino
- Complicações pós-operatórias
- Processos Patológicos
- Doenças Genitais, Masculino
- Doenças Urogenitais Masculinas
- Condições Patológicas, Anatômicas
- Distúrbios Gonadais
- Anomalias congénitas
- Hérnia
- Anormalidades urogenitais
- Hérnia Abdominal
- Doenças testiculares
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Dor, Pós-operatório
- Hérnia Inguinal
- Criptorquidismo
- Hidrocele Testicular
Outros números de identificação do estudo
Outros números de identificação do estudo
- FMBSUREC/08092026b/ Mikhael
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data (including primary outcome measures, demographic variables, FLACC pain scores, cumulative opioid consumption, and block execution metrics) will be made available to qualified academic researchers upon reasonable request submitted to the principal investigator, following publication of the primary trial results.
Prazo de Compartilhamento de IPD
Data will become available 3 months following peer-reviewed journal publication of the primary manuscript and will remain accessible for 3 years.
Critérios de acesso de compartilhamento IPD
Data will be shared with recognized medical and academic researchers who submit a sound scientific proposal and a signed data-use agreement to the principal investigator (at Kmnmk87@med.bsu.edu.eg).
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .